Stock in Focus: Biogen Inc (BIIB)

Company Profile:

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Recent News:

On May 29, 2020, Vir Biotechnology and Biogen Execute finalized a process development and manufacturing agreement to manufacture SARS-CoV-2 antibodies for potential COVID-19 treatment.

On May 19, 2020, Biogen Inc. announced new data from its robust multiple sclerosis (MS) treatment portfolio. Additional clinical data support VUMERITY® (diroximel fumarate) as an important oral treatment option in relapsing MS and reinforce the efficacy of TECFIDERA® (dimethyl fumarate).


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



BIIB’s strengths can be seen in its better growth, better profitability, better solvency and better efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, MACD is trying to cross back up and the RSI stands at 49.17 with positive bias. We rate Biogen Inc (BIIB) a STRONG BUY.

About the Author

has written 12772 stories on this site.

Copyright © 2012 Nine Stocks